The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Silverfoil13,
I still think we've got year or so to go before the selling starts. This will be a multi-bagger but I feel we need 1801 to get through the P1 trial first. Data is what it's all about.
Hopefully something happens sooner though!
Silverfoil13,
I find the charts are a very useful tool. They clearly show points of resistance and support. For Sareum I use this to to time my buys as I'm accumulating.
It also helps the nerves. For example in March when the SP was in free fall, it stabilised at 120 (2.4p old money), which just so happened to be the high from January 21. Funny how that works.
Mrdigit,
Just because I have a few posts in this BB doesn't mean I don't know how to read a chart. If you think posts on here = experience then you are very mistaken. It's very clear that the price pumps on news and dips during the silences.
It’s unlikely there will be/have been any serious offers for Scancell without trial data. Affinivax’s lead vaccine is heading into a Phase 3 trial. Looking at 80p or £1 would be a low ball offer for the potential of the IP that Scancell have. IMO we will need to wait at least 18 months for data from the phase 1 trials under way and hopefully the start or approval for phase 2 before any offers are made. Anything from £2 to £8 depending on data and which IP the buyer is after. The further Scancell progress with the trials, the higher the value.
We really do need some good news to stop the hemorraging SP following what the market perceived as a horrible RNS on the 26th January.
Modi1 news anyone?
It’s very strange that there hasn’t been a Diggle wiggle either. I do wonder if something (good) is going on in the background. The silence is deafening.
If Sareum were were a company generating revenue then consolidation could probably be perceived as being a bad idea. However, they do not generate any revenue but instead rely on investment to progress their IP. Consolidation in this case can be seen as good as it will allow them to attract institutional investors rather than having to look for a million here and a million there from individuals as they progress. To vote no to consolidation would just keep Sareum scrounging around for funds when they really need big investments to progress. Temporary pain for big gain (consolidation) or long term pain and a potential fire sale (no consolidation)? There’s only really one option.
RR,
Here’s the explanation.
https://www.google.co.uk/amp/s/mobile.reuters.com/article/amp/idUSL1N2SI07K